Evidence map›Paper›PMID 23389777›Full record

ReviewToxicologic pathology2013

Nanotechnology: toxicologic pathology.

Ann F Hubbs, Linda M Sargent, Dale W Porter, Tina M Sager, Bean T Chen, David G Frazer, Vincent Castranova, Krishnan Sriram, Timothy R Nurkiewicz, Steven H Reynolds and 5 more

Abstract readReview
In one paragraph

Review in Toxicologic pathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. A snapshot of gene therapy in Latin America.Genetics and molecular biology · 2014
    Review
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ann F HubbsHealth Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown, West Virginia 26505, USA. ahubbs@cdc.gov
Linda M Sargent
Dale W Porter
Tina M Sager
Bean T Chen
David G Frazer
Vincent Castranova
Krishnan Sriram
Timothy R Nurkiewicz
Steven H Reynolds
Lori A Battelli
Diane Schwegler-Berry
Walter McKinney
Kara L Fluharty
Robert R Mercer

Funding

Remote Microvascular Dysfunction After Particulate Matter ExposureR01ES015022 · NIEHS · WEST VIRGINIA UNIVERSITY · PI NURKIEWICZ, TIMOTHY R · 2007 to 2021
$4.9M
Intramural CDC HHS CC999999NIEHS NIH HHS R01 ES015022NIEHS NIH HHS R01-ES015022
6 · The paper itself

Abstract

Nanotechnology involves technology, science, and engineering in dimensions less than 100 nm. A virtually infinite number of potential nanoscale products can be produced from many different molecules and their combinations. The exponentially increasing number of nanoscale products will solve critical needs in engineering, science, and medicine. However, the virtually infinite number of potential nanotechnology products is a challenge for toxicologic pathologists. Because of their size, nanoparticulates can have therapeutic and toxic effects distinct from micron-sized particulates of the same composition. In the nanoscale, distinct intercellular and intracellular translocation pathways may provide a different distribution than that obtained by micron-sized particulates. Nanoparticulates interact with subcellular structures including microtubules, actin filaments, centrosomes, and chromatin; interactions that may be facilitated in the nanoscale. Features that distinguish nanoparticulates from fine particulates include increased surface area per unit mass and quantum effects. In addition, some nanotechnology products, including the fullerenes, have a novel and reactive surface. Augmented microscopic procedures including enhanced dark-field imaging, immunofluorescence, field-emission scanning electron microscopy, transmission electron microscopy, and confocal microscopy are useful when evaluating nanoparticulate toxicologic pathology. Thus, the pathology assessment is facilitated by understanding the unique features at the nanoscale and the tools that can assist in evaluating nanotoxicology studies.

Indexed as

NanotechnologyPathologyToxicologyAnimalsHumans

Identifiers

PMID23389777
PMCPMC4665093

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.